Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.175 (1.80%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.70
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Dec 2023 17:36

RNS Number : 1181Y
Scancell Holdings Plc
28 December 2023

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B63D3314

Issuer Name

SCANCELL HOLDINGS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Vulpes Investment Management Pte Ltd

City of registered office (if applicable)

SG

Country of registered office (if applicable)

Singapore

4. Details of the shareholder

Name

City of registered office

Country of registered office

Vulpes Life Sciences Fund

Cayman Islands

Cayman Islands

5. Date on which the threshold was crossed or reached

28-Dec-2023

6. Date on which Issuer notified

28-Dec-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

12.920000

0.000000

12.920000

119910847

Position of previous notification (if applicable)

14.36

14.36

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B63D3314

119910847

12.920000

Sub Total 8.A

119910847

12.920000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLFLFFDFALTFIV
Date   Source Headline
18th Apr 20182:29 pmRNSResult of Placing and Subscription and PDMR
18th Apr 201811:05 amRNSSecond Price Monitoring Extn
18th Apr 201811:00 amRNSPrice Monitoring Extension
18th Apr 20187:00 amRNSTechnology acquired from University of Nottingham
18th Apr 20187:00 amRNSProposed Placing, Subscription and Open Offer
3rd Apr 20187:00 amRNSManufacturing agreement with The PolyPeptide Group
16th Feb 201811:30 amRNSScancell to present at the Calculus Investor Forum
15th Feb 20187:15 amRNSHardman Res. - Validating multiple opportunities
15th Feb 20187:00 amRNSCollaboration agreement with ISA Pharmaceuticals
12th Feb 20187:00 amRNSPublication highlights potential of SCIB1 therapy
9th Feb 20187:00 amRNSEuropean patent application allowed for grant
8th Feb 20187:00 amRNSScancell member of team shortlisted for CRUK award
1st Feb 20187:00 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSHalf-year Report
9th Jan 20187:00 amRNSScancell to collaborate with BioNTech
14th Dec 20177:00 amRNSScancell and CRUK to advance cancer immunotherapy
11th Oct 20179:44 amRNSResult of AGM
10th Oct 20177:00 amRNSDirectorate Change
14th Sep 20177:00 amRNSNotice of AGM
13th Sep 20177:00 amRNSFinal Results
11th Sep 20177:00 amRNSPresents Moditope Data at Immunotherapy Conference
29th Aug 20177:00 amRNSOncimmune and Scancell Present Autoantibodies Data
11th Jul 20177:00 amRNSContinued Progress on SCIB1
26th Jun 20177:00 amRNSDNA ImmunoBody Patent Granted in Europe
22nd May 201712:59 pmRNSHolding(s) in Company
19th May 20172:47 pmRNSHolding(s) in Company
19th May 20177:00 amRNSHolding(s) in Company
11th May 201712:09 pmRNSResults of Placing
11th May 20177:00 amRNSProposed Placing to Raise up to £5.0 million
13th Apr 201712:39 pmRNSChange of Registered Office
20th Mar 20177:00 amRNSImmuno-Oncology Summit Europe 2017
13th Mar 20177:15 amRNSHardman Research: SCIB development update
1st Mar 20177:00 amRNSHolding(s) in Company
31st Jan 20177:00 amRNSInterim Results
30th Jan 20177:00 amRNSPartnership to Advance Lung Cancer Clinical Trials
3rd Jan 201711:33 amRNSResearch Update - Amendment
3rd Jan 20177:00 amRNSResearch Update
14th Nov 20167:00 amRNSWorld Immunotherapy Congress and Biotech and Money
18th Oct 20165:42 pmRNSResults of AGM
10th Oct 20167:00 amRNSPreparing SCIB2 for clinical study in lung cancer
26th Sep 20167:15 amRNSHardman Report: New frontiers in T-cell activation
23rd Sep 20165:24 pmRNSNotice of AGM - Amendment
23rd Sep 20163:28 pmRNSNotice of AGM
16th Sep 20167:00 amRNSFinal Results
7th Sep 20167:00 amRNSNewsMakers in the Biotech Industry Conference
22nd Aug 20167:00 amRNSAppointment of Non-Executive Director
21st Jul 20167:00 amRNSEurogentec manufacturing agreement
20th Jul 20167:00 amRNSExtension to Ichor Commercial Option
13th Jul 20167:00 amRNSPeer-reviewed publication on Moditope® platform
6th Jul 20167:00 amRNSSCIB1 compelling survival data in melanoma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.